The impact of angiotensin-converting enzyme inhibitors on managed care: Economic, clinical, and humanistic outcomes

American Journal of Managed Care

Volumn 6, Issue 3 SUPPL., 2000, Pages

  Reeder, C E ^a   Gourley, Greta A ^b   Wurtzbacher, J Doug ^b   Reed, Pamala ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; LISINOPRIL; QUINAPRIL; RAMIPRIL;

ANTIHYPERTENSIVE THERAPY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC NEPHROPATHY; DRUG COST; HEART INFARCTION; HUMAN; HYPERTENSION; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH INSURANCE; ORGANIZATION AND MANAGEMENT; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MANAGED CARE PROGRAMS; TREATMENT OUTCOME;

EID: 0034137138     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Bulpitt CJ, Beevers DG, Butler A, et al. The survival of treated hypertensive patients and their causes of death: A report from the DHSS hypertensive care computing project (DHCCP). J Hypertens 1986;4(1):93-99.
2. National Heart, Lung, and Blood Institute: Fact Book Fiscal Year 1996 Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 1997.
3. Stamler J. Blood pressure and high blood pressure. Aspects of risk. Hypertension 1991;18(suppl 3):95-107.
4. Parmley WW. Cost-effective management of heart failure. Clin Cardiol 1996;19(3):240-242.
5. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: The case of heart failure. Arch Intern Med 1999;159(15):1690-1700.
6. Shulman NB. Economic issues relating to access to medications. Cardiovasc Clin 1991;21(3):75-82.
7. Jacobs RP. Hypertension and managed care. Am J Manag Care 1998;4(suppl 12): S749-S752; discussion: S753-S756.
8. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research. Clin Ther 1993;15(6):1121-1132; discussion: 1120.
9. Program NHBPE. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health, 1997.
10. Gerbrandt KR, Yedinak KC. Formulary management of ACE inhibitors. Pharmacoeconomics 1996;10(6):594-613.
11. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998;18(3):588-599.
12. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor. A guide to selection. Drugs 1995;49(4):516-535.
13. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319(23):1517-1525.
14. Johnston D, Duffin D. Drug-patient interactions and their relevance in the treatment of heart failure. Am J Cardiol 1992;70(10):109C-112C.
15. Vertes V, Haynie R. Comparative pharmacokinetics of captopril, enalapril, and quinapril. Am J Cardiol 1992;69(10):8C-16C.
16. Zannad F. Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993;46(suppl 2):172-1781; discussion: 182.
17. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA 1995;274(6):462] [see comments]. JAMA 1995;273(18):1450-1456.
18. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I [see comments]. Eur Heart J 1999;20(2):136-139.
19. Jackson G. ATLAS: High dose lisinopril is superior to low dose in heart failure [editorial]. Int J Clin Pract 1998;52(3):139.
20. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy [see comments]. Lancet 1997;349:1493-1497.
21. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993;153(21):2426-2435.
22. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993;118(2):129-138.
23. Nielsen FS, Sato A, Ali S, et al. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients [see comments]. Diabetes Care 1998;21(5):804-809.
24. Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999;33(suppl 1):S16-S20; discussion: S41-S43.
25. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials, J Am Coll Cardiol 1999;33(3):598-604.
26. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. Oxford: Oxford University Press, 1997.
27. Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics. Cincinnati, OH: Harvey Whitney Books, 1996.
28. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension [see comments]. Ann Intern Med 1990;112(3):192-202.
29. Kawachi I, Malcolm LA. The benefits of treating mild to moderate hypertension. A quantitative estimation of the life expectancy gains from pharmacological reduction of blood pressure. J Clin Epidemiol 1989;42(9):905-912.
30. Shepard DS, Hodgkin D. Cost effectiveness of intensive treatment of hypertension. Am J Manag Care 1998;4(suppl 12):S765-S769; discussion: S770.
31. Stason WB, Weinstein MC. Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension. N Engl J Med 1977;296(13):732-739.
32. Stevens RD, Bingley LJ Jr, Boger M, El-Wanni J, Kaston J. Variability in the management of hypertension and cost-effectiveness: Methodology, community care results and potential cost reductions. Soc Sci Med 1984;18(9):767-774.
33. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden: An analysis of the criteria for intervention and the choice of drug treatment. J Hum Hypertens 1996;10(suppl 2):S23-S26.
34. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension [see comments]. JAMA 1990;263(3):407-413.
35. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model. Am J Public Health 1987;77(11):1417-1426.
36. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: A reappraisal. J Hypertens 1991;9(3):199-208.
37. Briscoe TA, Dearing CJ. Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. Am J Health Syst Pharm 1996;53(18):2191-2193.
38. Hilleman DE, Mohiuddin SM, Lucas BD Jr, Stading JA, Stoysich AM, Ryschon K. Costminimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994;16(1):88-102; discussion: 87.
39. Rodby RA, Lewis EJ. ACE inhibition in diabetic patients. Economic implications. Pharmacoeconomics 1996;10(4):315-320.
40. Borch-Johnsen K. ACE inhibitors in patients with diabetes mellitus. Clinical and economic considerations. Pharmacoeconomics 1996;9(5):392-398.
41. Garattini L, Brunetti M, Salvioni F, Barosi M. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. Pharmacoeconomics 1997;12(1):67-75.
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [see comments] [published erratum appears in N Engl J Med 1993;330(2):152]. N Engl J Med 1993;329(20):1456-1462.
43. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators (see comments). N Engl J Med 1992;327(10):669-677.
44. Szucs TD. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Am J Hypertens 1997;10(10 Pt 2):272S-279S.
45. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction [see comments]. J Am Coll Cardiol 1995;26(4):914-919.
46. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [see comments]. N Engl J Med 1991;325(5):293-302.
47. Glick H, Cook J, Kinosian B. Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial. J Card Failure 1995;1:371-379.
48. Butler JR, Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust N Z J Med 1996;26(1):89-95.
49. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100(9):1016-1030.
50. Eccles M, Freemantle N, Mason J. North of England evidence based development project: Guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure [see comments]. Br Med J 1998;316:1369-1375.
51. McMurray JJ, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios postmyocardial infarction. Eur Heart J 1997;18(9):1411-1415.
52. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [see comments]. Lancet 1993;342:821-828.
53. Fourth International Study of Infarct Survival, Collaborative Group (ISIS-4): A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
54. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction [see comments]. Lancet 1994;343:1115-1122.
55. Bulpitt CJ, Fletcher AE. Importance of well-being to hypertensive patients. Am J Med 1988;84(1 B):40-46.
56. Bulpitt CJ, Fletcher AE. Quality of life evaluation of antihypertensive drugs. Pharmacoeconomics 1992; 1 (2):95-102.
57. Skaer TL, Sclar DA, Robison LM. Noncompliance with antihypertensive therapy. Economic consequences. Pharmacoeconomics 1996;9(1):1-4.
58. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314(26):1657-1664.
59. McCorvey E Jr, Wright JT Jr, Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clin Pharm 1993;12(4):300-305.
60. Blumenthal JA, Ekelund LG, Emery CF. Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. Clin Pharmacol Ther 1990;48(4):447-454.
61. Herrick AL, Waller PC, Berkin KE, et al. Comparison of enalapril and atenolol in mild to moderate hypertension. Am J Med 1989;86(4):421-426.
62. Beto JA, Bansal VK. Quality of life in treatment of hypertension. A metaanalysis of clinical trials. Am J Hypertens 1992;5:125-133.
63. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group [see comments]. N Engl J Med 1993;328(13):907-913.
64. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure [see comments]. N Engl J Med 1991;325(5):303-310.
65. Rector TS, Johnson G, Dunkman WB, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(suppl 6):VI71-77.
66. Wolfel EE. Effects of ACE inhibitor therapy on quality of life in patients with heart failure. Pharmacotherapy 1998;18(6):1323-1334.